-The Times of India CHENNAI: In a major step to make cancer cure affordable for patients and their families, the retail prices of several anti-cancer drugs, including commonly used chemotherapy injections for lung cancer treatment, have been slashed by up to 87% by the drug price control authority. After reviewing the data collected from drug manufacturers, the National Pharmaceutical Pricing Authority’s May 15 memorandum has brought nine anti-cancer drugs in its price...

-The Hindu Business Line The 60% jump over last year is due to DBT in fertiliser where Rs.39,230 cr was transferred Mumbai: Direct benefit transfer of subsidies in cash and kind crossed the Rs.3-lakh crore mark in 2018-19 to 123.8 crore beneficiaries through over 351-crore transactions. Official data reveals that DBT in both cash and kind amounted to Rs.3,06,260 crore last fiscal, a 60 per cent jump from Rs.1,90,870.9 crore in 2017-18. A significant...

-Newsclick.in In an interview, the ‘father’ of India’s Green Revolution, says while technology is necessary, policies on procurement and public distribution are far more important in making agriculture economically viable and sustainable in the country. No one has played a more instrumental role in India’s self-sufficiency in food production than Dr MS Swaminathan — world-renowned agricultural scientist, known as the ‘Father of Green Revolution in India’. After getting a PhD from Cambridge...

-The Hindu Business Line Eminent agriculture scientist MS Swaminathan, Chairman of the much discussed Farmers’ Commission whose report mooted an MSP at 50 per cent above cost, feels that income support can be given in the form of free inputs or higher procurement as well. While welcoming ‘PM-Kisan’, he says cash transfer should not become a form of patronage and that the focus should shift from loan write-offs to long-term policies....

-The Times of India NEW DELHI: In what is being seen as an attempt to delay launch of low priced generic medicines, multinational drug makers have asked the government to create a registry providing information about all drug applications pending manufacturing and marketing approval. The proposal, if accepted by the government, will help ‘big pharma’ pre-emptively challenge generic drug makers in court for allegedly infringing upon their patents and in turn blocking...